Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Cirrhosis article more useful, or one of our other health articles.
Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.
See also the separate Primary Biliary Cirrhosis article.
Cirrhosis is a diffuse hepatic process characterised by fibrosis and the conversion of normal liver architecture into structurally abnormal nodules. Cirrhosis represents the final histological pathway for a wide variety of liver diseases. The progression to cirrhosis is very variable and may occur over weeks or many years. Around 80-90% of the liver parenchyma needs to be destroyed before there are clinical signs of liver failure. However, there is often a poor correlation between the histological findings and the clinical picture.
The fibrosis causes distortion of the hepatic vasculature and can lead to an increased intrahepatic resistance and portal hypertension. Portal hypertension can lead to oesophageal varices as well as hypoperfusion of the kidneys, water and salt retention and increased cardiac output. Damage to liver cells (hepatocytes) causes impaired liver function and the liver becomes less able to synthesise important substances such as clotting factors and is also less able to detoxify other substances (see also the separate Liver Failure article).
Causes of cirrhosis
A number of chronic liver diseases can lead to cirrhosis. The cirrhotic process can take from weeks to many years to develop, depending on the underlying cause and other factors, including patient response to the disease process. For example, chronic hepatitis C infection can take up to 40 years to progress to cirrhosis in some people.
- Common causes of cirrhosis include:
- Less common causes include:
- Primary biliary cirrhosis.
- Biliary obstruction (may be due to biliary atresia/neonatal hepatitis, congenital biliary cysts or cystic fibrosis).
- Autoimmune hepatitis.
- Inherited metabolic disorders - eg, tyrosinaemia, Wilson's disease, porphyria, alpha-1-antitrypsin deficiency, glycogen storage diseases.
- Sarcoidosis or other granulomatous disease.
- Primary sclerosing cholangitis.
- Venous outflow obstruction in Budd-Chiari syndrome or veno-occlusive disease.
- Drugs and toxins including methotrexate, amiodarone and isoniazid[2, 6].
- Congestive heart failure or tricuspid regurgitation (although this is rarely seen now due to improved management).
- Infections including congenital and tertiary syphilis and schistosomiasis.
- It is difficult to estimate the exact prevalence of cirrhosis, as previously undiagnosed cirrhosis is often found at post-mortem.
- There are an estimated 30,000 people living with cirrhosis in the UK and at least 7,000 new cases being diagnosed each year. The number of people living with both alcoholic cirrhosis and non-alcohol-related cirrhosis seems to be rising.
- There is concern that there are growing levels of dangerous alcohol consumption in the UK which may lead to increased numbers of people with cirrhosis.
- An analysis in the Lancet showed that between 1960 and 2002, total recorded alcohol consumption in Britain doubled. The same report showed that between 1987-1991, and 1997-2001, cirrhosis mortality in men in Scotland more than doubled (104% increase) and in England and Wales rose by over two thirds (69%). Mortality in women increased by almost half (46% in Scotland and 44% in England and Wales).
- Alcoholic liver disease and hepatitis C are the most common causes in developed countries.
- Hepatitis B is the most common cause in parts of Asia and in sub-Saharan Africa.
- There may also be a genetic predisposition to cirrhosis which may explain the variable rates of its development in people with similar risk factors (such as alcohol abuse or hepatitis C infection).
- Continued alcohol consumption increases the rate of progression of cirrhosis from any cause.
- Risk factors for the development of cirrhosis in those with chronic hepatitis C infection:
- Regular (moderate) alcohol consumption.
- Age >50 years.
- Being male.
- Risk factors for the development of cirrhosis in those with NASH[11, 12]:
- Older age.
- Insulin resistance or type 2 diabetes.
Cirrhosis is often asymptomatic until there are obvious complications of liver disease. Up to 40% of people with cirrhosis may be asymptomatic. Blood testing for other reasons may reveal abnormal liver function and prompt further investigation which shows cirrhosis.
The history should include a thorough enquiry for possible underlying causes of cirrhosis, including a full drug and alcohol history (including over-the-counter drugs, complementary medicines and recreational drugs), risk factors for hepatitis infection, and family history of autoimmune or liver diseases.
Cirrhosis may present with vague symptoms such as fatigue, malaise, anorexia, nausea and weight loss. In advanced, decompensated liver disease, presentation may include:
- Easy bruising.
- Poor concentration and memory.
- Bleeding oesophageal varices.
- Spontaneous bacterial peritonitis.
Physical signs are variable and depend upon the extent of disease.
- Cutaneous features of cirrhosis include:
- Scratch marks secondary to pruritus.
- Spider angiomata/naevi (mainly found on the trunk and face).
- Skin telangiectasias (called 'paper money skin').
- Palmar erythema.
- Petechiae or purpura.
- Hair loss.
- White nails (horizontal white bands or a proximal white nail plate; sign of hypoalbuminaemia).
- Finger clubbing.
- Dupuytren's contracture.
- Other signs include:
- Hepatomegaly and a nodular liver.
- Gynaecomastia and male hair loss pattern.
- Hypogonadism/testicular atrophy/amenorrhoea (due to the direct toxic effect of alcohol in alcoholic cirrhosis or iron in haemochromatosis).
- Kayser-Fleischer ring (a brown-green ring of copper deposit around the cornea, pathognomonic for Wilson's disease).
- Signs of portal hypertension include:
- Ascites (can be detected clinically when ≥1.5 litres of fluid is present).
- Caput medusae (veins seen radiating from the umbilicus).
- Enlarged spleen.
- Signs of hepatic encephalopathy:
- Asterixis ('flapping tremor'); suggests hepatic encephalopathy. To detect asterixis, take the patient's hand and gently hyperextend the wrist and joints of the hand, pushing gently on the tips of the four fingers. Ignore the thumb. Hold that position for several seconds and you will feel a slow, clonic flexion-relaxation movement against your hand if asterixis is present.
These will depend to a considerable extent upon clinical suspicion of the aetiology.
- LFTs: should include aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), bilirubin, gamma-glutamyltransferase (gamma-GT); AST and ALT are raised due to hepatocyte damage; gamma-GT is high in active alcoholics.
- Albumin: there is hypoalbuminaemia in advanced cirrhosis.
- FBC: occult bleeding may produce anaemia; hypersplenism may cause thrombocytopenia; macrocytosis can suggest alcohol abuse.
- Renal function tests and electrolytes: hyponatraemia may be present (due to increased activity of antidiuretic hormone). Poor renal function may represent hepatorenal syndrome.
- Red cell folate: alcohol abuse is often associated with a diet inadequate in folate.
- Coagulation screen: abnormalities of coagulation are a sensitive test of liver function; prothrombin time is reduced in advanced cirrhosis.
- Ferritin: low ferritin may indicate iron deficiency from diet or blood loss; ferritin is raised in haemochromatosis.
- Viral antibody screen: to look for evidence of hepatitis B or C infection.
- Fasting glucose/insulin/triglycerides and uric acid levels: these should be measured if NASH is suspected.
- Autoantibody screen: anti-mitochondrial antibodies are a very strong indicator of primary biliary cirrhosis.
- Alpha-1-antitrypsin level: to assess for alpha-1-antitrypsin deficiency.
- Ceruloplasmin and urinary copper: to look for Wilson's disease.
- Fasting transferrin saturation and HFE (haemochromatosis C282Y) mutation: along with a raised ferritin, these tests can screen for haemochromatosis.
- Ultrasound scan of liver and possibly CT or MRI scan: their main use is to detect complications of cirrhosis, such as splenomegaly, ascites or hepatocellular carcinoma.
- CXR: this may show an elevated diaphragm and even pleural effusion (due to the passage of ascitic fluid across the diaphragm).
Either transient elastography or acoustic radiation force impulse imaging (whichever is available) should be used to diagnose cirrhosis for people with NAFLD and advanced liver fibrosis. Liver biopsy should be considered to diagnose cirrhosis in people for whom transient elastography is not suitable.
Offer retesting for cirrhosis every 2 years for:
- People diagnosed with alcohol-related liver disease.
- People with hepatitis C virus infection who have not shown a sustained virological response to antiviral therapy.
- People with NAFLD and advanced liver fibrosis.
Classification systems for cirrhosis
The Child-Pugh-Turcotte (CPT) classification system is a widely used and validated way to estimate prognosis in those with cirrhosis.
|Child-Pugh (Child-Pugh-Turcotte) Classification|
|Criterion||Score 1 point||Score 2 points||Score 3 points|
|Serum albumin (g/L)||>35||28-35||<28|
|Serum bilirubin (total)||<34 μmol/L (<2 mg/dL)||34-50 μmol/L (2-3 mg/dL)||>50 μmol/L (>3 mg/dL)|
|International Normalized Ratio (INR)||<1.7||1.7-2.2||>2.2|
|Ascites||Absent||Controlled medically||Poorly controlled|
|Encephalopathy||Absent||Controlled medically||Poorly controlled|
|A score of 5-6 is class A (life expectancy 15-20 years); a score of 7-9 is class B (life expectancy 4-14 years); a score of 10-15 is class C (life expectancy 1-3 years). This aligns with a perioperative mortality (for abdominal surgery) of 10%, 30%, and 80% respectively.|
The aim of treatment is to delay progression of cirrhosis and to prevent and/or treat any complications of cirrhosis.
- Specific treatment for the underlying cause.
- Ensure adequate nutrition, including calorie and protein intake.
- Alcohol: the most important measure for someone with alcoholic cirrhosis is for them to stop drinking. Continued alcohol intake can also increase the rate of progression of cirrhosis from any cause.
- Zinc deficiency is often seen in patients with cirrhosis and treatment with zinc supplements may be helpful.
- Pruritus is a common complaint in cholestatic and non-cholestatic liver diseases. Mild itching complaints may respond to treatment with antihistamines and topical ammonium lactate. Colestyramine is the mainstay of therapy for the pruritus of liver disease. Rifampicin has helped some patients unresponsive to colestyramine. Severe pruritus may require treatment with ultraviolet light or plasmapheresis.
- Patients with cirrhosis may develop osteoporosis and those at risk of osteoporosis should be given preventative treatment. See also the separate Osteoporosis Risk Assessment and Primary Prevention article.
- Regular exercise should be encouraged and is important to prevent muscle wasting.
- Prophylactic antibiotic use in patients with cirrhosis and upper gastrointestinal bleeding significantly reduces bacterial infections and seems to reduce all-cause mortality, bacterial infection mortality, rebleeding events and length of hospitalisation.
- Patients with chronic liver disease should receive vaccination to protect them against hepatitis A, influenza and pneumococci.
- Drug prescribing: care is essential to avoid any drug that may not be properly metabolised in the presence of liver failure, have an adverse effect on the degree of liver failure or be a cause of drug-induced liver disease. See prescribing in the separate Drug-induced Hepatitis article.
- Liver transplantation is the ultimate treatment for cirrhosis and end-stage liver disease. See the separate Liver Transplantation article.
- For the future: various antifibrotic drugs have been postulated that may slow down, or even reverse, the fibrotic process in cirrhosis and clinical trials have been carried out/are underway. Stem cell or hepatocyte transplantation aimed at restoring liver function is also being investigated.
If complications develop, the patient should be transferred to a specialised liver unit where there is the expertise to manage the complications and where the patient can also be assessed as to their suitability for liver transplantation.
Anaemia, thrombocytopenia and coagulopathy
- Anaemia may result from folate deficiency, haemolysis or hypersplenism.
- Thrombocytopenia is usually secondary to hypersplenism and decreased levels of thrombopoietin.
- Coagulopathy results from decreased hepatic production of coagulation factors. If present, cholestasis causes decreased vitamin K absorption, leading to reduced hepatic production of factors II, VII, IX and X.
- Patients with cirrhosis also may develop fibrinolysis and disseminated intravascular coagulation.
- These can occur as a result of portal hypertension.
- See the separate Oesophageal Varices article for more details.
- Young people and adults with cirrhosis and upper gastrointestinal bleeding should be given prophylactic intravenous antibiotics at presentation.
- Offer endoscopic variceal band ligation for the primary prevention of bleeding for people with cirrhosis who have medium to large oesophageal varices.
- This is a common feature of cirrhosis.
- It is an accumulation of excessive fluid within the peritoneal cavity due to the increased plasma volume 'spilling over' into the abdominal cavity.
- The clinical detection of ascites is described in the separate Abdominal Examination article but much smaller volumes may be detected by ultrasound.
- Its aetiology and management are discussed in the separate Ascites and Ascites Tapping articles.
- Consider a transjugular intrahepatic portosystemic shunt for people with cirrhosis who have refractory ascites.
- Offer prophylactic oral ciprofloxacin or norfloxacin for people with cirrhosis and ascites with an ascitic protein of 15 g/litre or less, until the ascites has resolved.
Spontaneous bacterial peritonitis
- Ascites may be associated with spontaneous bacterial peritonitis.
- It is thought to be caused by the spread of bacteria across the gut wall and/or haematogenous bacterial spread. Escherichia coli is among the most common organisms implicated.
- This may be prevented by adequately treating ascites and treating those with high neutrophil counts in their ascitic fluid (>250 neutrophils/ml) with empirical intravenous antibiotics and albumin[3, 15].
- Patients who survive an episode of spontaneous bacterial peritonitis should receive long-term prophylaxis with oral antibiotics such as norfloxacin, levofloxacin or trimethoprim[3, 15].
- Cirrhosis is a major risk factor for hepatocellular carcinoma. See the separate Hepatocellular Carcinoma article.
- The risk varies according to the cause of cirrhosis.
- It is most often associated with cirrhosis caused by hepatitis C infection, followed by cirrhosis caused by hereditary haemochromatosis.
- Worldwide, hepatocellular carcinoma as a result of cirrhosis secondary to hepatitis B infection causes a large number of deaths.
- The risk of hepatocellular carcinoma is lower in those with alcoholic cirrhosis (8% five-year occurrence) or primary biliary cirrhosis (4% five-year occurrence).
- Patients with cirrhosis should be screened for hepatocellular carcinoma.
- The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) guidelines recommend at least one screening per year for hepatocellular carcinoma in patients with cirrhosis, using imaging with ultrasonography, triphasic CT or gadolinium-enhanced MRI. Screening using serum alpha-fetoprotein is no longer recommended because of its poor sensitivity and specificity.
Surveillance for hepatocellular carcinoma
Offer ultrasound (with or without measurement of serum alpha-fetoprotein) every 6 months as surveillance for hepatocellular carcinoma (HCC) for people with cirrhosis who do not have hepatitis B virus infection.
Surveillance in adults with chronic hepatitis B:
- Perform 6-monthly surveillance for HCC by hepatic ultrasound and alpha-fetoprotein testing in people with significant fibrosis (METAVIR stage greater than or equal to F2 or Ishak stage greater than or equal to 3) or cirrhosis.
- In people without significant fibrosis or cirrhosis (METAVIR stage less than F2 or Ishak stage less than 3), consider 6-monthly surveillance for HCC if the person is older than 40 years and has a family history of HCC and HBV DNA greater than or equal to 20,000 IU/ml.
- Do not offer surveillance for HCC in people without significant fibrosis or cirrhosis (METAVIR stage less than F2 or Ishak stage less than 3) who have HBV DNA less than 20,000 IU/ml and are younger than 40 years.
Surveillance for oesophageal varices
After a diagnosis of cirrhosis, offer upper gastrointestinal endoscopy to detect oesophageal varices.
For people in whom no oesophageal varices have been detected, offer surveillance using upper gastrointestinal endoscopy every 3 years.
Other less common complications can include:
- Cirrhotic cardiomyopathy - there is cardiac hypertrophy and a blunted stress response of the heart. May cause significant problems perioperatively and mean that liver transplantation may be too dangerous.
- Hepatopulmonary syndrome - there is pulmonary arteriolar vasodilation, shunting and hypoxaemia. Transplantation may reverse this.
- Portopulmonary hypertension - an irreversible condition that can occur in those with refractory ascites.
- Surgery and general anaesthesia have increased risks in the patient with cirrhosis.
- This depends on the underlying cause and on the success of the treatment of the underlying cause. Prognosis is discussed in the separate articles for the conditions that can lead to cirrhosis.
- If someone with alcoholic cirrhosis continues to drink alcohol, the rate of decompensation can be rapid.
- Patients with fulminant hepatic failure have a 50-80% mortality rate unless they receive a liver transplant.
- Worldwide, the most important factor in prevention of cirrhosis is immunisation against hepatitis B.
- There is no vaccine against hepatitis C but some treatments may delay progression and alcohol must be avoided.
- Sensible drinking is essential for everyone and patients should be advised about the recommended limits.
- There are various separate articles providing further information about the assessment and management of harmful drinking and alcohol dependence: Alcohol Use Disorders Identification Test (AUDIT), CAGE Questionnaire, Alcohol-related Problems, Alcoholism - Recognition and Assessment and Alcoholism and Alcohol Abuse - Management.
- Beware of hepatotoxic medications, including herbal remedies.
Further reading and references
Management of alcohol-related liver disease; European Association for the Study of the Liver - EASL (2018)
Liver disease; NICE Quality standard (June 2017)
Tsochatzis EA, Bosch J, Burroughs AK; Liver cirrhosis. Lancet. 2014 May 17383(9930):1749-61. doi: 10.1016/S0140-6736(14)60121-5. Epub 2014 Jan 28.
Heidelbaugh JJ, Bruderly M; Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006 Sep 174(5):756-62.
Schuppan D, Afdhal NH; Liver cirrhosis. Lancet. 2008 Mar 8371(9615):838-51.
Lagana SM, Moreira RK, Lefkowitch JH; Hepatic granulomas: pathogenesis and differential diagnosis. Clin Liver Dis. 2010 Nov14(4):605-17. doi: 10.1016/j.cld.2010.07.005.
Bittencourt PL, Couto CA, Ribeiro DD; Portal vein thrombosis and budd-Chiari syndrome. Clin Liver Dis. 2009 Feb13(1):127-44. doi: 10.1016/j.cld.2008.10.002.
Velayudham LS, Farrell GC; Drug-induced cholestasis. Expert Opin Drug Saf. 2003 May2(3):287-304.
Dunbar JK, Crombie IK; The rising tide of liver Cirrhosis mortality in the UK: can its halt be predicted? Alcohol Alcohol. 2011 Jul-Aug46(4):459-63. doi: 10.1093/alcalc/agr042. Epub 2011 May 3.
Leon DA, McCambridge J; Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet. 2006 Jan 7367(9504):52-6.
Cirrhosis in over 16s - assessment and management; NICE Guideline (July 2016)
Sinn DH, Paik SW, Kang P, et al; Disease progression and the risk factor analysis for chronic hepatitis C. Liver Int. 2008 Dec28(10):1363-9. doi: 10.1111/j.1478-3231.2008.01860.x.
Clark JM; The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006 Mar40(3 Suppl 1):S5-10.
Farrell GC, Larter CZ; Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006 Feb43(2 Suppl 1):S99-S112.
Leung PS, Rossaro L, Davis PA, et al; Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology. 2007 Nov46(5):1436-42.
Kim YK, Kim Y, Shim SS; Thoracic complications of liver cirrhosis: radiologic findings. Radiographics. 2009 May-Jun29(3):825-37. doi: 10.1148/rg.293085093.
Heidelbaugh JJ, Sherbondy M; Cirrhosis and chronic liver failure: part II. Complications and treatment. Am Fam Physician. 2006 Sep 174(5):767-76.
Wiesner R, Edwards E, Freeman R, et al; Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003 Jan124(1):91-6.
Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, et al; Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal Cochrane Database Syst Rev. 2010 Sep 8(9):CD002907.
Kleinegris MC, Bos MH, Roest M, et al; Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. J Thromb Haemost. 2014 Oct12(10):1647-57. doi: 10.1111/jth.12706. Epub 2014 Sep 30.
van Erpecum KJ; Ascites and spontaneous bacterial peritonitis in patients with liver cirrhosis. Scand J Gastroenterol Suppl. 2006(243):79-84.
Llovet JM, Burroughs A, Bruix J; Hepatocellular carcinoma. Lancet. 2003 Dec 6362(9399):1907-17.
Hepatitis B (chronic) : diagnosis and managements; NICE Clinical Guideline (June 2013 - last updated October 2017)